Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.534
Filtrar
1.
Drug Discov Ther ; 14(3): 129-134, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32669521

RESUMO

The aim of this randomized, single-blind, active-controlled pilot study was to investigate the clinical efficacy of oral supplementation with Verbascox®, a proprietary herbal extract capable of inhibiting human cyclooxygenase-2 (COX-2), in patients with mild-to-moderate osteoarthritis (OA) of the knee. Patients in the control group (n = 50) did not undergo any treatment (watchful waiting). Patients in the Verbascox® group (n = 50) received oral supplementation (800 mg/day) with the herbal extract for 2 weeks. The final study group consisted of patients (n = 50) who received celecoxib, a known pharmacological inhibitor of COX-2, 200 mg/day for 2 weeks. Examining physicians and laboratory personnel were blinded to group assignment, whereas patients were unblinded. All participants were evaluated using standard measures of pain relief and improvement in functional capacity at baseline, after 1 week, and at the end of the 2-week treatment course. Moreover, serum levels of substance P (SP), a member of the tachykinin family of neuropeptides involved in pain perception, were measured at the three time points. Both Verbascox® and celecoxib reduced pain, improved functional capacity, and lowered serum SP levels at 2 weeks compared with baseline, without significant inter-arm differences. Both Verbascox® and celecoxib showed a limited number of treatment-emergent adverse events. In summary, oral supplementation with Verbascox® (800 mg/day) in patients with mild-to-moderate OA of the knee is as effective and safe as a standard therapeutic dose of celecoxib in terms of pain relief and improvement in functional capacity after a 2-week treatment course.


Assuntos
Celecoxib/uso terapêutico , Inibidores de Ciclo-Oxigenase 2/uso terapêutico , Osteoartrite do Joelho/tratamento farmacológico , Medição da Dor/efeitos dos fármacos , Medição da Dor/métodos , Preparações de Plantas/uso terapêutico , Adulto , Idoso , Celecoxib/farmacologia , Inibidores de Ciclo-Oxigenase 2/farmacologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Preparações de Plantas/farmacologia , Método Simples-Cego , Resultado do Tratamento
2.
Am J Chin Med ; 48(4): 779-792, 2020.
Artigo em Inglês | MEDLINE | ID: covidwho-298629

RESUMO

Since the outbreak of Corona Virus Disease 2019 (COVID-19) in Hubei province, the epidemic scale has increased rapidly, and no effective antiviral drug therapy has been identified yet. This study aimed to evaluate the adjuvant efficacy of Natural Herbal Medicine (NHM) combined with Western medicine in the treatment of COVID-19. We performed a retrospective, 1:1 matched, case-control study of the first cohort of hospitalized COVID-19-confirmed cases (January 17, 2020 to January 28, 2020). A total of 22 of the 36 confirmed patients were included in this study, split into two groups of 11: the NHM group (NHM combined standard Western medicine treatment) and control group (standard Western medicine treatment alone). All patients received appropriate supportive care and regular clinical and laboratory monitoring. Main evaluation indicators included improvement of clinical symptoms such as fever, cough and diarrhea after hospitalization; pathogen nucleic acid test result of respiratory tract and fecal specimens of the patient after hospitalization, and change of chest CT examination after hospitalization. The duration of fever in the NHM group ([Formula: see text] days) was significantly shorter than that in the control group ([Formula: see text] days) ([Formula: see text]). During the whole hospitalization period, the number of cases with diarrhea in the NHM group (two cases) was less than that in the control group (eight cases) ([Formula: see text]). Compared with the control group ([Formula: see text]), the duration for improvement (DI) of chest CT in the NHM group ([Formula: see text]) was significantly shorter ([Formula: see text]). Our results suggest that NHM could improve the clinical symptoms of COVID-19 patients and may be effective in treating COVID-19; thus, a larger, prospective, randomized, controlled clinical trial should be conducted to further evaluate the adjuvant efficacy of NHM in the treatment of COVID-19.


Assuntos
Infecções por Coronavirus/tratamento farmacológico , Fitoterapia/métodos , Preparações de Plantas/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Adulto , Idoso , Betacoronavirus , Estudos de Casos e Controles , China , Estudos de Coortes , Terapia Combinada , Infecções por Coronavirus/complicações , Infecções por Coronavirus/diagnóstico por imagem , Medicamentos de Ervas Chinesas/uso terapêutico , Feminino , Hospitalização , Humanos , Masculino , Medicina Tradicional Chinesa , Pessoa de Meia-Idade , Pandemias , Pneumonia Viral/complicações , Pneumonia Viral/diagnóstico por imagem , Estudos Retrospectivos , Tomografia Computadorizada por Raios X , Resultado do Tratamento
4.
Autoimmun Rev ; 19(7): 102570, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: covidwho-155061

RESUMO

Now COVID-19 is causing a severe public health emergency and the mortality is rapidly increasing all over the world. In the current pandemic era, although there have been many efforts to diagnose a number of patients with symptoms or close contacts, there is no definite guideline for the initial therapeutic approach for them and therefore, many patients have been dying due to a hyperinflammatory immunological reaction labeled as "cytokine storm". Severe patients are hospitalized and the treatment is done, though they have not been established yet. Currently, however, no treatment is provided for those who are isolated at home or shelter until they get severe symptoms, which will increase the harms to the patients. In this review, we discuss some important points dedicated to the management of patients with COVID-19, which should help reducing morbidity and mortality. In this era, we suggest 7 recommendations to rescue the patients and to reduce the morbidity and mortality due to COVID-19 based on the immunological point of view.


Assuntos
Infecções por Coronavirus/mortalidade , Infecções por Coronavirus/terapia , Pneumonia Viral/mortalidade , Pneumonia Viral/terapia , Antibacterianos/uso terapêutico , Betacoronavirus , Infecções por Coronavirus/imunologia , Síndrome da Liberação de Citocina/virologia , Humanos , Hidroxicloroquina/uso terapêutico , Pulmão/fisiopatologia , Morbidade , Antissépticos Bucais , Sprays Nasais , Pandemias , Preparações de Plantas/uso terapêutico , Pneumonia Viral/imunologia , Povidona-Iodo/uso terapêutico , Sambucus/química , Abandono do Hábito de Fumar , Esteroides/uso terapêutico
6.
Autoimmun Rev ; 19(7): 102570, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32376397

RESUMO

Now COVID-19 is causing a severe public health emergency and the mortality is rapidly increasing all over the world. In the current pandemic era, although there have been many efforts to diagnose a number of patients with symptoms or close contacts, there is no definite guideline for the initial therapeutic approach for them and therefore, many patients have been dying due to a hyperinflammatory immunological reaction labeled as "cytokine storm". Severe patients are hospitalized and the treatment is done, though they have not been established yet. Currently, however, no treatment is provided for those who are isolated at home or shelter until they get severe symptoms, which will increase the harms to the patients. In this review, we discuss some important points dedicated to the management of patients with COVID-19, which should help reducing morbidity and mortality. In this era, we suggest 7 recommendations to rescue the patients and to reduce the morbidity and mortality due to COVID-19 based on the immunological point of view.


Assuntos
Infecções por Coronavirus/mortalidade , Infecções por Coronavirus/terapia , Pneumonia Viral/mortalidade , Pneumonia Viral/terapia , Antibacterianos/uso terapêutico , Betacoronavirus , Infecções por Coronavirus/imunologia , Síndrome da Liberação de Citocina/virologia , Humanos , Hidroxicloroquina/uso terapêutico , Pulmão/fisiopatologia , Morbidade , Antissépticos Bucais , Sprays Nasais , Pandemias , Preparações de Plantas/uso terapêutico , Pneumonia Viral/imunologia , Povidona-Iodo/uso terapêutico , Sambucus/química , Abandono do Hábito de Fumar , Esteroides/uso terapêutico
7.
Zhongguo Zhen Jiu ; 40(5): 533-5, 2020 May 12.
Artigo em Chinês | MEDLINE | ID: mdl-32394662

RESUMO

Professor YANG Jun believes that infantile cerebral palsy is located in the brain and closely related to the kidney. The clinical treatment should focus on the brain theory and root at the kidney. In pathogenesis, infantile spastic cerebral palsy refers to flaccidity of yang and spasticity of yin. The principle of treatment should be balancing yin and yang, promoting the circulation of the governor vessel and regulating the spirit/mind. In clinical treatment, the comprehensive therapy of acupuncture and herbal medicine is adopted. In acupuncture, the acupoints on the head and the face are dominant and the body acupoints are selected rigorously and precisely. The herbal formula with Carya cathayensis Sarg and Scorpio is used and taken orally with warm water. In acupoint application treatment, Borneolum Syntheticum and Radix et Rhizoma Asari are the main herbal medicines for the external application at Shenque (CV 8) and Baihui (GV 20). All of the above therapies are used in combination to co-achieve the effect of regaining consciousness, opening orifices and benefiting the intelligence. The clinical therapeutic effect of this comprehensive therapy is significant.


Assuntos
Terapia por Acupuntura , Paralisia Cerebral/terapia , Preparações de Plantas/uso terapêutico , Pontos de Acupuntura , Medicina Herbária , Humanos
8.
Am J Chin Med ; 48(4): 779-792, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32420751

RESUMO

Since the outbreak of Corona Virus Disease 2019 (COVID-19) in Hubei province, the epidemic scale has increased rapidly, and no effective antiviral drug therapy has been identified yet. This study aimed to evaluate the adjuvant efficacy of Natural Herbal Medicine (NHM) combined with Western medicine in the treatment of COVID-19. We performed a retrospective, 1:1 matched, case-control study of the first cohort of hospitalized COVID-19-confirmed cases (January 17, 2020 to January 28, 2020). A total of 22 of the 36 confirmed patients were included in this study, split into two groups of 11: the NHM group (NHM combined standard Western medicine treatment) and control group (standard Western medicine treatment alone). All patients received appropriate supportive care and regular clinical and laboratory monitoring. Main evaluation indicators included improvement of clinical symptoms such as fever, cough and diarrhea after hospitalization; pathogen nucleic acid test result of respiratory tract and fecal specimens of the patient after hospitalization, and change of chest CT examination after hospitalization. The duration of fever in the NHM group ([Formula: see text] days) was significantly shorter than that in the control group ([Formula: see text] days) ([Formula: see text]). During the whole hospitalization period, the number of cases with diarrhea in the NHM group (two cases) was less than that in the control group (eight cases) ([Formula: see text]). Compared with the control group ([Formula: see text]), the duration for improvement (DI) of chest CT in the NHM group ([Formula: see text]) was significantly shorter ([Formula: see text]). Our results suggest that NHM could improve the clinical symptoms of COVID-19 patients and may be effective in treating COVID-19; thus, a larger, prospective, randomized, controlled clinical trial should be conducted to further evaluate the adjuvant efficacy of NHM in the treatment of COVID-19.


Assuntos
Infecções por Coronavirus/tratamento farmacológico , Fitoterapia/métodos , Preparações de Plantas/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Adulto , Idoso , Betacoronavirus , Estudos de Casos e Controles , China , Estudos de Coortes , Terapia Combinada , Infecções por Coronavirus/complicações , Infecções por Coronavirus/diagnóstico por imagem , Medicamentos de Ervas Chinesas/uso terapêutico , Feminino , Hospitalização , Humanos , Masculino , Medicina Tradicional Chinesa , Pessoa de Meia-Idade , Pandemias , Pneumonia Viral/complicações , Pneumonia Viral/diagnóstico por imagem , Estudos Retrospectivos , Tomografia Computadorizada por Raios X , Resultado do Tratamento
9.
Sci Total Environ ; 728: 138859, 2020 Aug 01.
Artigo em Inglês | MEDLINE | ID: covidwho-102005

RESUMO

Since December 2019, a respiratory pandemic named as coronavirus disease 2019 (Covid-19) caused by a new coronavirus named as SARS-CoV-2, has taken the world by storm. The symptoms are fever, malaise, and cough which resolve in a few days in most cases; but may progress to respiratory distress and organ failure. Transmission is through droplet infection or fomites, but other modes such as airborne transmission and oro-fecal transmission are also speculated. Research is underway to develop effective vaccines and medicines for the disease. In such a scenario, we present the measures described in Unani system of medicine for health protection during epidemics. Unani is a traditional system of medicine developed during the middle ages, which employs natural drugs of herbal, animal and mineral origin for treatment. In Unani medicine, during an epidemic, apart from isolation and quarantine, three measures are of utmost importance, (i) purification of surroundings using certain herbal drugs as fumigants or sprays, (ii) health promotion and immune-modulation, and (iii) use of health-protecting drugs and symptom-specific drugs. Drugs such as loban (Styrax benzoides W. G. Craib), sandroos (Hymenaea verrucosa Gaertn.) za'fran (Crocus sativus L.), vinegar etc. are prescribed in various forms. Scientific researches on these drugs reveal the presence of a number of pharmacologically active substances, which may provide a new insight into the management of infections and epidemics.


Assuntos
Infecções por Coronavirus , Medicina Unani , Pandemias , Pneumonia Viral , Animais , Betacoronavirus , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/prevenção & controle , Humanos , Pandemias/prevenção & controle , Preparações de Plantas/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/prevenção & controle
10.
Eur Rev Med Pharmacol Sci ; 24(7): 4030-4034, 2020 04.
Artigo em Inglês | MEDLINE | ID: covidwho-124272

RESUMO

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain that was discovered in 2019 and has not been previously identified in humans. On December 31st 2019 World Health Organization (WHO) was informed of a cluster of cases with pneumonia of unknown origin from Wuhan City, Hubei province of China. The WHO announced in February 2020 that COVID-19 is the official name of the coronavirus diseases. A total of 519,899 confirmed cases with 23,592 deaths linked to this pathogen as on March 27, 2020 have been reported. Due to increasing number of infected people across the continents and huge loss to human life, the WHO has declared the novel COVID-19 outbreak a pandemic. A pandemic is defined as the "worldwide spread" of a new disease. Currently, no COVID-19 specific treatments have been approved by the United States Food and Drug Administration (US-FDA). However, the current treatment options include hydroxychloroquine, tocilizumab, remdesivir, lopinavir-ritonavir (Kaletra®), and nitazoxanide. In recent past, some natural herbal compounds have demonstrated encouraging anti-viral properties. This article attempted to summarize available information on the reported anti-viral activity of some natural products.


Assuntos
Infecções por Coronavirus/tratamento farmacológico , Fitoterapia , Preparações de Plantas/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Betacoronavirus , Humanos , Pandemias , Organização Mundial da Saúde
11.
Eur Rev Med Pharmacol Sci ; 24(7): 4030-4034, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32329879

RESUMO

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain that was discovered in 2019 and has not been previously identified in humans. On December 31st 2019 World Health Organization (WHO) was informed of a cluster of cases with pneumonia of unknown origin from Wuhan City, Hubei province of China. The WHO announced in February 2020 that COVID-19 is the official name of the coronavirus diseases. A total of 519,899 confirmed cases with 23,592 deaths linked to this pathogen as on March 27, 2020 have been reported. Due to increasing number of infected people across the continents and huge loss to human life, the WHO has declared the novel COVID-19 outbreak a pandemic. A pandemic is defined as the "worldwide spread" of a new disease. Currently, no COVID-19 specific treatments have been approved by the United States Food and Drug Administration (US-FDA). However, the current treatment options include hydroxychloroquine, tocilizumab, remdesivir, lopinavir-ritonavir (Kaletra®), and nitazoxanide. In recent past, some natural herbal compounds have demonstrated encouraging anti-viral properties. This article attempted to summarize available information on the reported anti-viral activity of some natural products.


Assuntos
Infecções por Coronavirus/tratamento farmacológico , Fitoterapia , Preparações de Plantas/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Betacoronavirus , Humanos , Pandemias , Organização Mundial da Saúde
12.
Sci Total Environ ; 728: 138859, 2020 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-32334163

RESUMO

Since December 2019, a respiratory pandemic named as coronavirus disease 2019 (Covid-19) caused by a new coronavirus named as SARS-CoV-2, has taken the world by storm. The symptoms are fever, malaise, and cough which resolve in a few days in most cases; but may progress to respiratory distress and organ failure. Transmission is through droplet infection or fomites, but other modes such as airborne transmission and oro-fecal transmission are also speculated. Research is underway to develop effective vaccines and medicines for the disease. In such a scenario, we present the measures described in Unani system of medicine for health protection during epidemics. Unani is a traditional system of medicine developed during the middle ages, which employs natural drugs of herbal, animal and mineral origin for treatment. In Unani medicine, during an epidemic, apart from isolation and quarantine, three measures are of utmost importance, (i) purification of surroundings using certain herbal drugs as fumigants or sprays, (ii) health promotion and immune-modulation, and (iii) use of health-protecting drugs and symptom-specific drugs. Drugs such as loban (Styrax benzoides W. G. Craib), sandroos (Hymenaea verrucosa Gaertn.) za'fran (Crocus sativus L.), vinegar etc. are prescribed in various forms. Scientific researches on these drugs reveal the presence of a number of pharmacologically active substances, which may provide a new insight into the management of infections and epidemics.


Assuntos
Infecções por Coronavirus , Medicina Unani , Pandemias , Pneumonia Viral , Animais , Betacoronavirus , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/prevenção & controle , Humanos , Pandemias/prevenção & controle , Preparações de Plantas/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/prevenção & controle
13.
Artigo em Inglês | MEDLINE | ID: mdl-32120948

RESUMO

The milky juice of the greater celandine herb has been used in folk medicine and in homeopathy for treatment of viral warts for years. However, classical medicine fails to use properties of celandine herbs in treatment of diseases induced by papilloma viruses. Nevertheless, dermatological outpatient clinics are regularly visited by patients reporting efficacy of milky sap isolated from celandine herb in treatment of their own viral warts. Authors of this report decided to analyze the respective world literature in order to critically evaluate the potential for treatment of viral dermal warts using the milky sap of celandine. Moreover, the case of a 4-year old boy was presented, the parents of whom applied the milky sap of celandine on viral warts on hands. Thus, Ch. majus may be a potential therapeutic modality for skin warts, especially in a young patients, where conventional therapy may be difficult to apply.


Assuntos
Chelidonium/química , Preparações de Plantas/uso terapêutico , Verrugas/terapia , Antivirais/uso terapêutico , Pré-Escolar , Mãos , Humanos , Masculino
14.
BMC Complement Med Ther ; 20(1): 43, 2020 Feb 11.
Artigo em Inglês | MEDLINE | ID: mdl-32046707

RESUMO

BACKGROUND: Despite the large number of trials conducted using herbal oral care products for the reduction of dental plaque or gingivitis, results are conflicting and inconclusive. OBJECTIVE: To assess the effectiveness of herbal oral care products compared to conventional products in reducing dental plaque and gingivitis adults. METHODS: We searched the following databases for Randomised controlled trials (RCTs): MEDLINE Ovid, EMBASE Ovid etc. which yielded 493 trails. Of which 24 RCTs comparing herbal toothpaste or mouth rinse with over the counter toothpaste or mouth rinse in adults aged 18 to 65 years were included. Two authors extracted information and assessed the methodological quality of the included studies using Risk of Bias. Meta-analyses using the random-effects model were conducted for four outcomes for tooth paste and mouth rinse respectively. Mean difference (MD) or standardized mean difference (SMD) were used to estimate the effect, with 95% confidence intervals. RESULTS: A total of 1597 adults participated in 24 RCT studies. These were classified as herbal toothpaste (HTP) (15 trials, 899 participants) and herbal mouth rinse (HMR) (9 trials, 698 participants) compared with non-herbal toothpaste (NHTP) or non-herbal mouth rinse (NHMR). We found that HTP was superior over NHTP (SMD 1.95, 95% CI (0.97-2.93)) in plaque reduction. The long-term use of NHMR was superior in reduction of dental plaque over HMR (SMD -2.61, 95% (CI 4.42-0.80)). From subgroup analysis it showed that HTP was not superior over fluoride toothpaste (SMD 0.99, 95% CI (0.14-2.13)) in reducing dental plaque. However, HTP was favoured over non-fluoride toothpaste (SMD 4.64, 95% CI (2.23-7.05)). CONCLUSION: For short-term reduction in dental plaque, current evidence suggests that HTP is as effective as compared to NHTP; however, evidence is from low quality studies.


Assuntos
Placa Dentária/tratamento farmacológico , Gengivite/tratamento farmacológico , Antissépticos Bucais , Higiene Bucal/métodos , Preparações de Plantas/uso terapêutico , Cremes Dentais , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto
15.
Mol Med Rep ; 21(3): 1461-1470, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32016479

RESUMO

The present study was designed to elucidate the underlying mechanisms of Bao Gui capsule (BGC) against hyperandrogenism, insulin resistance and leptin resistance of PCOS. Letrozole was used to induce a PCOS model in rats, which were then randomly divided into four groups (n=9): Control, Model, high­dose BGC (BGC­H) and low­dose BGC (BGC­L) group. Serum levels of follicle­stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), estradiol (E2), insulin, leptin, and interleukin (IL)­1ß, IL­6 and tumor necrosis factor­α (TNF­α) in the hypothalamus were determined by ELISA. Protein levels of cytochrome P450c17α and cytochrome P450 aromatase (P450arom) in ovaries were determined by immunohistochemistry and western blot analysis. Additionally, the expression of GLUT4 in uterus and muscle tissue, and NF­κB, IKKß and SOCS3 mRNA levels in the hypothalamus were evaluated. BGC significantly reduced body weight gain and decreased serum levels of LH/FSH, T, log T/E2, insulin and leptin compared with the PCOS model rats. Furthermore, BGC markedly reduced the expression of P450c17α and significantly increased the expression of P450arom in ovaries, and increased the expression of GLUT4 in uterus and muscle tissues. BGC also effectively reduced the level of IL­6 and TNF­α, and the expression of IKKß, NF­κB and SOCS3 in the hypothalamus of PCOS model rats. These results suggest that BGC may effectively improve hyperandrogenism, insulin resistance, endometrial receptivity and the low­grade chronic inflammation in the hypothalamus.


Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Hiperandrogenismo/tratamento farmacológico , Resistência à Insulina , Fitoterapia , Preparações de Plantas/uso terapêutico , Síndrome do Ovário Policístico/tratamento farmacológico , Animais , Citocinas/sangue , Endométrio/efeitos dos fármacos , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Transportador de Glucose Tipo 4/metabolismo , Hiperandrogenismo/metabolismo , Hipotálamo/metabolismo , Insulina/sangue , Leptina/sangue , Hormônio Luteinizante/sangue , Síndrome do Ovário Policístico/metabolismo , Ratos , Testosterona/sangue , Útero/metabolismo
16.
BMJ Case Rep ; 13(2)2020 Feb 10.
Artigo em Inglês | MEDLINE | ID: mdl-32047089

RESUMO

We present a case of a 68-year-old man with chronic hepatitis C infection, with no evidence of chronic liver disease during the first years of follow-up, diagnosed with a hepatocellular carcinoma (HCC) with 40 mm (α-fetoprotein (AFP) 205 ng/mL). He underwent segmental liver resection and pathology analysis was consistent with HCC and cirrhosis in the adjacent liver. Four months after surgery, AFP raised up to 126 661 ng/mL and abdominal MRI revealed a multinodular HCC. Patient rejected treatment with sorafenib and started megestrol and an herbal medicine, soursop (Annona muricata). Six months later, AFP markedly decreased (28 ng/mL) and abdominal MRI showed decreasing size and number of lesions. At 5 years of follow-up, he has no evidence of HCC. Spontaneous regression of HCC is a rare condition and the underlying mechanism is unclear. In this case there is a temporal relation between the start of megestrol and Annona muricata and HCC regression.


Assuntos
Carcinoma Hepatocelular/terapia , Neoplasias Hepáticas/terapia , Megestrol/uso terapêutico , Regressão Neoplásica Espontânea , Preparações de Plantas/uso terapêutico , Idoso , Annona , Antineoplásicos Hormonais/uso terapêutico , Hepatite C Crônica , Humanos , Masculino
18.
Talanta ; 211: 120710, 2020 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-32070601

RESUMO

Screening diagnostic biomarkers can be challenging due to the complexity of traditional Chinese medicine (TCM) and ambiguous pharmacological mechanisms. In this study, we reported an integrated strategy for accurately screening diagnostic biomarkers based on metabolomics coupled with network pharmacology. First, a feasible pharmacological model was established through systems pharmacology and based on metabolomics-based techniques to explore diagnostic biomarkers. While the components satisfying the q-value < 0.05, fold change (FC) ≥ 1.2 or FC ≤ 0.8, coefficient of variance (CV) ≤ 30%(QC) and the variable importance in the project (VIP) value > 1 are considered to be diagnostic biomarkers. Second, the ingredients were retained only when oral bioavailability (OB), Caco-2 permeability, drug half-life, TPSA and drug likeness (DL) satisfied the criteria (OB ≥ 40%; Caco-2 ≥ -0.4; HL ≥ 4 h; TPSA˂140; DL ≥ 0.18) suggested by the TCMSP database. Moreover, ingredients that exhibit extensive biological activity in TCM are also retained. Third, the effect targets of TCM were screened using the TCMSP database, Swiss Target Prediction and STICH online software. Disease targets were gathered from the therapeutic target database (TTD), PharmGkb and TCMSP database. Hub genes were screened by potential protein-protein interaction (PPI) network pharmacology analysis. Finally, a metabolic network pathway is established between the diagnostic biomarker and the hub gene. In the network analysis of metabolic pathways, most of the genes involved in this pathway are the second-step-obtained hub genes, which can explain the accuracy of the identified biomarkers. The proposed integrated strategy was successfully applied to explore the mechanism of action of Pulsatilla decoction (PD) in the treatment of acute ulcerative colitis (UC). Based on this integrated strategy, 23 potential biomarkers of acute UC treated with PD were identified. In conclusion, the integrated strategy provides novel insights into network pharmacology and metabolomics as effective tools to illuminate the mechanism of action of TCM.


Assuntos
Colite Ulcerativa/tratamento farmacológico , Coptis , Fraxinus , Phellodendron , Preparações de Plantas/uso terapêutico , Pulsatilla , Animais , Biomarcadores/metabolismo , Células CACO-2 , Colite Ulcerativa/metabolismo , Colite Ulcerativa/patologia , Colo/efeitos dos fármacos , Colo/metabolismo , Colo/patologia , Fezes/química , Humanos , Masculino , Medicina Tradicional Chinesa , Metabolômica , Camundongos Endogâmicos BALB C , Farmacologia/métodos , Fitoterapia , Preparações de Plantas/farmacologia
19.
Clin Oral Investig ; 24(4): 1591-1597, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31916035

RESUMO

OBJECTIVES: The present research aimed to explore the effect of a mucoadhesive containing Jasminum grandiflorum leaves on the process of oral wound healing in animal samples. MATERIALS AND METHODS: The present double-blinded research was conducted on animals. To this aim, 28 rats were randomly selected and assigned to groups of control and experiment. The lesion was created by punch no. 3 in the midline of the mandibular labial mucosa of all mice. Each group received either a medicine or a placebo exclusively coded. The extent of contraction and wound healing was clinically assessed. To compare the two research groups, chi-squared test, repeated-measure ANOVA, and Mann-Whitney U test were run. SPSS software was used to do the statistical analyses. RESULTS: Statistically significant differences were found between the percentage of wound contraction on the 3rd day (40.91% vs. 16.5%, p = 0.04) and the 7th day (92.9% vs. 69.2%, p = 0.05), wound recovery (57.1% vs. 21.4%, p = 0.05) and degree of inflammation on the 7th day (p = 0.00), type (p = 0.04) and thickness of epithelium (p = 0.00) and type of connective tissue (p = 0.00) on the 14th day. CONCLUSION: Investigations showed that the drug was more effective than the placebo in accelerating wound healing in clinical and histopathological terms. CLINICAL RELEVANCE: Accelerating wound healing in dental treatments and oral ulcers can also affect the quality of life of individuals.


Assuntos
Jasminum/química , Úlceras Orais/tratamento farmacológico , Preparações de Plantas/uso terapêutico , Cicatrização , Animais , Biópsia , Masculino , Distribuição Aleatória , Ratos
20.
Complement Ther Med ; 48: 102253, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31987237

RESUMO

OBJECTIVES: To determine the effectiveness of including an herbal compress in a traditional Thai massage regimen for the care of low back pain in the elderly. DESIGN AND METHODS: This study was a randomised controlled trial. The sample consisted of 140 patients suffering from non-specific chronic low back pain, who were randomly assigned to either the TTM (n = 70) or TMH (n = 70) group. The primary outcome was pain intensity (Visual Analogue Scale), and the secondary outcomes were disability, back performance and quality of life. The outcome measurements were assessed at baseline, 6 weeks and 15 weeks. RESULTS: There were no statistically significant differences in the primary and secondary outcomes between the two study groups (p-value > 0.05). Although improvement was observed for both groups in pain intensity, disability, quality of life, and back performance. CONCLUSIONS: There was no additional benefit of including an herbal compress in a regimen of Thai massage for the care of low back pain in the elderly.


Assuntos
Dor Lombar/terapia , Massagem/métodos , Preparações de Plantas/uso terapêutico , Plantas Medicinais , Idoso , Terapia Combinada , Avaliação da Deficiência , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medição da Dor , Qualidade de Vida , Tailândia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA